About mogamulizumab
Anti-CCR4 monoclonal antibody
Used for
- Treats mycosis fungoides and Sézary syndrome, types of cutaneous T-cell lymphoma.
- Used in adults whose disease has returned or not responded to previous systemic treatment.
Usual adult dose
1 mg/kg by intravenous infusion: weekly for four doses, then every two weeks.
Common side effects
- Infusion-related reactions
- Rash
- Fatigue
- Diarrhea
Important warnings
- Can cause serious skin reactions, including severe rash.
- May cause infections or immune complications, including after stem-cell transplantation.
- Infusion reactions can be severe; monitoring is required during treatment.
- Can harm an unborn baby; effective contraception is recommended during treatment and for three months afterward.
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for three months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the last dose.
Interactions
- Medicines that suppress the immune system may increase risks, especially around stem-cell transplantation.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.